Abstract
In abiraterone- and/or enzalutamide-refractory metastatic castration-resistant prostate cancer (mCRPC) patients, selinexor led to prostate-specific antigen and/or radiographic responses in a subset of patients, indicating clinical activity in this indication.Despite twice-a-week dosing and maximal symptomatic management, selinexor was associated with significant anorexia, nausea, and fatigue in mCRPC patients refractory to second-generation anti-androgen therapies, limiting further clinical development in this patient population.This study highlights the challenge of primary endpoint selection for phase II studies in the post-abiraterone and/or post-enzalutamide mCRPC space. Selinexor is a first-in-class selective inhibitor of nuclear export compound that specifically inhibits the nuclear export protein Exportin-1 (XPO-1), leading to nuclear accumulation of tumor suppressor proteins. This phase II study evaluated the efficacy and tolerability of selinexor in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone and/or enzalutamide. Fourteen patients were enrolled. Selinexor was initially administered at 65 mg/m2 twice a week (days 1 and 3) and was subsequently reduced to 60 mg flat dose...Continue Reading
References
Apr 24, 1997·Nature·E A Nigg
Dec 31, 1997·Nature·M FukudaE Nishida
Jan 21, 2004·Nature Reviews. Cancer·Tweeny R KauPamela A Silver
May 27, 2011·The New England Journal of Medicine·Johann S de BonoUNKNOWN COU-AA-301 Investigators
Aug 17, 2012·The New England Journal of Medicine·Howard I ScherUNKNOWN AFFIRM Investigators
Dec 12, 2012·The New England Journal of Medicine·Charles J RyanUNKNOWN COU-AA-302 Investigators
Jun 3, 2014·The New England Journal of Medicine·Tomasz M BeerUNKNOWN PREVAIL Investigators
Jul 16, 2014·Oncotarget·Janet MendoncaSushant Kachhap
Oct 7, 2014·Journal of Hematology & Oncology·Giovanni Luca GravinaClaudio Festuccia
Jul 17, 2015·JAMA Oncology·Emmanuel S AntonarakisJun Luo
Dec 2, 2015·BMC Cancer·Giovanni Luca GravinaClaudio Festuccia
Mar 2, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Albiruni R Abdul RazakAmit Mahipal
May 18, 2016·Prostate Cancer and Prostatic Diseases·E S AntonarakisJ Luo
May 24, 2016·Leukemia·J EtchinA T Look
Jun 5, 2016·JAMA Oncology·Howard I ScherRyan Dittamore
Jul 28, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mrinal M GounderAlbiruni Ryan Abdul Razak
Aug 11, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas B AlexanderJeffrey E Rubnitz
Nov 1, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas VercruysseDirk Daelemans
May 5, 2017·Blood·John KuruvillaMartin Gutierrez
Citations
May 8, 2018·Cancers·Irfana MuqbilRamzi M Mohammad
Jan 21, 2020·Expert Opinion on Pharmacotherapy·Klaus PodarSundar Jagannath
Nov 20, 2018·Oncotarget·Amro AboukameelAsfar S Azmi
Nov 9, 2018·International Journal of Hematologic Oncology·Chetasi Talati, Kendra L Sweet
Jun 17, 2020·Leukemia & Lymphoma·Janek S WalkerRosa Lapalombella
Nov 25, 2018·Cells·Friederike K Kosyna, Reinhard Depping
Jun 4, 2020·Journal of Hematology & Oncology·Nancy G Azizian, Yulin Li
Aug 21, 2019·Drugs·Yahiya Y Syed
Nov 12, 2020·Nature Reviews. Clinical Oncology·Asfar S AzmiRamzi M Mohammad
Apr 29, 2021·Investigational New Drugs·Kyaw Zin TheinAung Naing